Acute Myeloid Leukemia
The latest news, research, and perspectives in acute myeloid leukemia (AML). AML, an aggressive blood cancer, is the most common type of acute leukemia in adults and most often develops when myeloid cells that normally develop into the various types of mature blood cells instead form abnormal myeloblasts.
Advertisement
The study was conducted because it was “uncertain whether a fractionated schedule provides additional benefit."
Researchers analyzed prognostic impact of NPM1 MRD in a real-world cohort of patients with NPM1-mutated AML.
The primary endpoints were short-term event-free survival and overall survival in the intention-to-treat population.
The retrospective, observational study included adults who received their first allogeneic HSCT during their first remission.
The crew talk about AML and MDS in this episode of The HemOnc Pulse.
Dr. Erba answers this question and more in this interview with Dr. Chadi Nabhan.
Advertisement
Dr. Nath spoke transplant in patients with AML who are elderly and emphasized the need to include them in clinical trials.
Enrolled patients must be aged 75 years or older or aged 18-74 years with specific comorbidities.
The trial will enroll approximately 346 patients with treatment-naive TP53-mutated disease or biallelic 17p deletions.
Dr. Konopleva explains the controversy and what she sees on the horizon for MRD in AML.
The award recognizes a SOHO member who has significantly contributed to the advancement of blood cancer care and research.
This single-center retrospective study looked at outcomes from 18 patients with AML treated with venetoclax plus an HMA.
The changes brought about by molecular characterization have a profound impact on real-world clinical care for AML.
After a single induction cycle, the CR rate was 83% in patients with FLT3 mutations, with a composite CR rate of 89%.
The multicenter, single-arm phase II trial enrolled 42 adults aged 18 to 59 years who had newly diagnosed AML.
Researchers conducted a one-year landmark analysis to stratify outcomes for patients by relapse category.
The difference in infection rates between the treatment and placebo groups was not statistically significant.
The FDA approval of quizartinib is based upon results from the QuANTUM-First trial.
The NCRI AML18 trial evaluated the sequential addition of quizartinib to intensive chemotherapy in older adults with AML.
The “effect of gilteritinib was more pronounced” in patients who had detectable MRD than those who did not.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.